- Home
- SITC vs RCKT Comparison
SITC vs RCKT Comparison
Compare SITC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | RCKT |
|---|---|---|
| Founded | 1965 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 340.9M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | SITC | RCKT |
|---|---|---|
| Price | $6.24 | $3.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $12.63 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 107.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $139,962,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.23 | $2.19 |
| 52 Week High | $15.93 | $13.35 |
Technical Indicators
Market Signals| Indicator | SITC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 27.20 | 46.08 |
| Support Level | $6.24 | $3.30 |
| Resistance Level | $6.53 | $3.57 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 3.02 | 22.81 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.